Hansa Medical announces prospectus
October 27, 2015 03:00 ET
|
Hansa Medical AB
Important information
The information in this press release is not directed at persons located in
Australia, Canada, Hong Kong, Japan, New Zealand, the Republic of Korea,
Singapore, South Africa,...
Hansa Medical AB offentliggör prospekt
October 27, 2015 03:00 ET
|
Hansa Medical AB
Viktig information
Informationen i detta pressmeddelande riktar sig inte till personer som befinner
sig i Australien, Kanada, Hongkong, Japan, Nya Zeeland, Sydkorea, Singapore,
Sydafrika, Schweiz, USA...
Hansa Medicals aktier har godkänts för handel på Nasdaq Stockholm
October 22, 2015 02:00 ET
|
Hansa Medical AB
Viktig information
Informationen i detta pressmeddelande riktar sig inte till personer som befinner
sig i Australien, Kanada, Hongkong, Japan, Nya Zeeland, Sydkorea, Singapore,
Sydafrika, Schweiz, USA...
Hansa Medical’s shares admitted to trading on Nasdaq Stockholm
October 22, 2015 02:00 ET
|
Hansa Medical AB
Important information
The information in this press release is not directed at persons located in
Australia, Canada, Hong Kong, Japan, New Zealand, the Republic of Korea,
Singapore, South Africa,...
Hansa Medical applies for stock exchange listing
October 13, 2015 02:00 ET
|
Hansa Medical AB
Important information
The information in this press release is not directed at persons located in
Australia, Canada, Hong Kong, Japan, New Zealand, the Republic of Korea,
Singapore, South Africa,...
Hansa Medical ansöker om börsnotering
October 13, 2015 02:00 ET
|
Hansa Medical AB
Viktig information
Informationen i detta pressmeddelande riktar sig inte till personer som befinner
sig i Australien, Kanada, Hongkong, Japan, Nya Zeeland, Sydkorea, Singapore,
Sydafrika, Schweiz, USA...
Data från Hansa Medicals första fas II-studie med IdeS i sensitiserade patienter presenterade på ESOT 2015
September 15, 2015 02:30 ET
|
Hansa Medical AB
Data från Hansa Medicals första avslutade fas II studie med IdeS vid Akademiska
sjukhuset i Uppsala har idag har presenterats av studiens ansvariga kliniska
prövare, Tomas Lorant, MD, PhD, vid...
Data from Hansa Medical’s First Phase II study of IdeS in Sensitized Kidney Transplantation Patients Presented in Oral Session at ESOT 2015
September 15, 2015 02:30 ET
|
Hansa Medical AB
Swedish investigators presented data from the first completed phase II study of
IdeS in sensitized patients at the 17thCongress of the European Society for
Organ Transplantation (ESOT) in Brussels....
Hansa Medical receives FDA Orphan Drug Designation for IdeS
September 14, 2015 08:30 ET
|
Hansa Medical AB
Hansa Medical today announced that the U.S. Food and Drug Administration (FDA)
has granted orphan drug designation (ODD) to IdeS for the prevention of antibody
mediated organ rejection in solid organ...
Hansa Medical beviljas särläkemedelsstatus för IdeS i USA
September 14, 2015 08:30 ET
|
Hansa Medical AB
Hansa Medical meddelar att U.S. Food and Drug Administration (FDA) har beviljat
bolagets ansökan om särläkemedelsstatus (Orphan Drug Designation) för
läkemedelskandidaten IdeS för prevention av...